MagForce AG
MagForce AG operates in the field of nanotechnology-based cancer therapy in Germany and Poland. It offers NanoTherm, a therapy for the treatment of brain tumors; NanoPlan, a software that supports the attending physician in preparing the ideal treatment …
Medical - Instruments & Supplies
DE, Berlin [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -26256.38 | -16817.93 | -63.81 | |
| Graham Fair Price | 3071.14 | 43.14 | 1.36 | |
| PEG | inf | 0.00 | 1.18 | |
| Price/Book | -99.92 | < 0.005 | -3.64 | |
| Price/Cash Flow | 0.00 | 0.00 | 0.00 | |
| Prices/Earnings | 16.31 | -7.37 | -8.81 | |
| Price/Sales | -16.31 | 222.94 | 266.38 | |
| Price/FCF | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 0.00 | 0.38 | 0.38 | |
| Operating Margin | 0.00 | -4.63 | -4.63 | |
| ROA | -100.00 | < 0.005 | 0.00 | |
| ROE | 0.10 | < 0.005 | -99.90 | |
| ROIC | 0.21 | < 0.005 | -99.98 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.00 | -1.00 | inf | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.10 | 0.00 | inf | |
| EPS QOQ | -0.07 | 0.00 | inf | |
| FCF QOQ | 0.00 | 0.00 | 0.00 | |
| Revenue QOQ | 1.11 | 0.00 | inf | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Not Interpreted
Fundamentals
Leverage & Liquidity
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 90.47 | 117346.16 | 129604.69 | |
| Days Sales Outstanding (DSO) | 0.00 | 199136.47 | 100.00 | |
| Inventory Turnover | 0.99 | < 0.005 | -99.92 | |
| Debt/Capitalization | -2.32 | 0.49 | -78.90 | |
| Quick Ratio | 0.01 | 0.14 | 930.49 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | -0.89 | 896.74 | 100461.34 | |
| Cash | < 0.005 | 3.83 | 99900.66 | |
| Capex | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | 0.00 | 0.00 | 0.00 | |
| Revenue | 0.01 | 0.01 | 0.00 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad